Showing results (61-70 of 927) with videos related to

Sort By:
Pageof 93
The Lancet. Diabetes & Endocrinology|October 19, 2019
Opioid-induced endocrinopathiesAthanasios Fountas, Stan Van Uum, Niki Karavitaki
The Lancet. Diabetes & Endocrinology|October 19, 2019
Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early interventionDinesh Selvarajah, Debasish Kar, Kamlesh Khunti, et al.
The Lancet. Diabetes & Endocrinology|July 6, 2019
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trialKausik K Ray, Helen M Colhoun, Michael Szarek, et al.
The Lancet. Diabetes & Endocrinology|October 9, 2018
Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysisMark J Bolland, Andrew Grey, Alison Avenell
The Lancet. Diabetes & Endocrinology|March 7, 2022
Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysisFreddy J K Toloza, Arash Derakhshan, Tuija Männistö, et al.
The Lancet. Diabetes & Endocrinology|March 5, 2022
Osteoporosis in menTatiane Vilaca, Richard Eastell, Marian Schini
The Lancet. Diabetes & Endocrinology|September 7, 2016
Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial, Edward Gregg, John Jakicic, et al.
The Lancet. Diabetes & Endocrinology|September 20, 2016
Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trialCornelis A J van Beers, J Hans DeVries, Susanne J Kleijer, et al.
The Lancet. Diabetes & Endocrinology|September 22, 2016
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trialJuan P Frías, Cristian Guja, Elise Hardy, et al.
The Lancet. Diabetes & Endocrinology|June 4, 2017
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohortTracy A Williams, Jacques W M Lenders, Paolo Mulatero, et al.
Pageof 93